![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC33A1 |
Gene summary for SLC33A1 |
![]() |
Gene information | Species | Human | Gene symbol | SLC33A1 | Gene ID | 9197 |
Gene name | solute carrier family 33 member 1 | |
Gene Alias | ACATN | |
Cytomap | 3q25.31 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O00400 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9197 | SLC33A1 | LZE4T | Human | Esophagus | ESCC | 3.16e-13 | 3.74e-01 | 0.0811 |
9197 | SLC33A1 | LZE7T | Human | Esophagus | ESCC | 1.28e-02 | 1.36e-01 | 0.0667 |
9197 | SLC33A1 | LZE8T | Human | Esophagus | ESCC | 6.01e-06 | 1.71e-01 | 0.067 |
9197 | SLC33A1 | LZE21D1 | Human | Esophagus | HGIN | 7.34e-04 | 2.56e-01 | 0.0632 |
9197 | SLC33A1 | LZE24T | Human | Esophagus | ESCC | 4.23e-15 | 4.32e-01 | 0.0596 |
9197 | SLC33A1 | LZE21T | Human | Esophagus | ESCC | 3.76e-05 | 4.09e-01 | 0.0655 |
9197 | SLC33A1 | LZE6T | Human | Esophagus | ESCC | 1.03e-04 | 2.40e-01 | 0.0845 |
9197 | SLC33A1 | P1T-E | Human | Esophagus | ESCC | 1.71e-06 | 5.00e-01 | 0.0875 |
9197 | SLC33A1 | P2T-E | Human | Esophagus | ESCC | 7.10e-60 | 9.99e-01 | 0.1177 |
9197 | SLC33A1 | P4T-E | Human | Esophagus | ESCC | 3.13e-26 | 6.08e-01 | 0.1323 |
9197 | SLC33A1 | P5T-E | Human | Esophagus | ESCC | 2.14e-11 | 2.29e-01 | 0.1327 |
9197 | SLC33A1 | P8T-E | Human | Esophagus | ESCC | 2.53e-30 | 5.56e-01 | 0.0889 |
9197 | SLC33A1 | P9T-E | Human | Esophagus | ESCC | 2.62e-10 | 2.80e-01 | 0.1131 |
9197 | SLC33A1 | P10T-E | Human | Esophagus | ESCC | 4.43e-34 | 6.05e-01 | 0.116 |
9197 | SLC33A1 | P11T-E | Human | Esophagus | ESCC | 2.19e-09 | 3.08e-01 | 0.1426 |
9197 | SLC33A1 | P12T-E | Human | Esophagus | ESCC | 5.92e-15 | 3.34e-01 | 0.1122 |
9197 | SLC33A1 | P15T-E | Human | Esophagus | ESCC | 5.85e-19 | 4.12e-01 | 0.1149 |
9197 | SLC33A1 | P16T-E | Human | Esophagus | ESCC | 4.36e-28 | 5.82e-01 | 0.1153 |
9197 | SLC33A1 | P17T-E | Human | Esophagus | ESCC | 2.92e-05 | 2.59e-01 | 0.1278 |
9197 | SLC33A1 | P20T-E | Human | Esophagus | ESCC | 1.43e-17 | 3.81e-01 | 0.1124 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001593116 | Esophagus | HGIN | nucleobase-containing compound transport | 57/2587 | 222/18723 | 1.76e-06 | 6.52e-05 | 57 |
GO:190260017 | Esophagus | HGIN | proton transmembrane transport | 43/2587 | 157/18723 | 5.51e-06 | 1.75e-04 | 43 |
GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
GO:190260018 | Esophagus | ESCC | proton transmembrane transport | 88/8552 | 157/18723 | 5.62e-03 | 2.10e-02 | 88 |
GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
GO:00071789 | Oral cavity | OSCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 165/7305 | 355/18723 | 2.31e-03 | 1.02e-02 | 165 |
GO:19012642 | Oral cavity | OSCC | carbohydrate derivative transport | 44/7305 | 80/18723 | 2.67e-03 | 1.16e-02 | 44 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC33A1 | SNV | Missense_Mutation | c.1366T>C | p.Ser456Pro | p.S456P | O00400 | protein_coding | deleterious(0.01) | possibly_damaging(0.905) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
SLC33A1 | SNV | Missense_Mutation | novel | c.823G>A | p.Val275Ile | p.V275I | O00400 | protein_coding | tolerated(0.14) | benign(0.074) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
SLC33A1 | SNV | Missense_Mutation | novel | c.419N>A | p.Arg140His | p.R140H | O00400 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC33A1 | SNV | Missense_Mutation | c.1061N>A | p.Pro354His | p.P354H | O00400 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC33A1 | SNV | Missense_Mutation | c.1061N>A | p.Pro354His | p.P354H | O00400 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC33A1 | SNV | Missense_Mutation | c.549N>A | p.Phe183Leu | p.F183L | O00400 | protein_coding | deleterious(0) | possibly_damaging(0.775) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC33A1 | SNV | Missense_Mutation | c.1078N>T | p.Pro360Ser | p.P360S | O00400 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
SLC33A1 | SNV | Missense_Mutation | rs774339001 | c.1213G>A | p.Gly405Arg | p.G405R | O00400 | protein_coding | tolerated(0.15) | probably_damaging(0.993) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC33A1 | SNV | Missense_Mutation | novel | c.826N>A | p.Ala276Thr | p.A276T | O00400 | protein_coding | tolerated(0.13) | possibly_damaging(0.771) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC33A1 | SNV | Missense_Mutation | c.259A>G | p.Ile87Val | p.I87V | O00400 | protein_coding | tolerated(0.16) | possibly_damaging(0.557) | TCGA-BW-A5NP-01 | Liver | liver hepatocellular carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | sorafenib | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9197 | SLC33A1 | TRANSPORTER | 178101262 | |||
9197 | SLC33A1 | TRANSPORTER | US8592431, 457 | |||
9197 | SLC33A1 | TRANSPORTER | US8592431, 181 | |||
9197 | SLC33A1 | TRANSPORTER | US8592431, 185 |
Page: 1 |